Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …

Cisplatin (cis-diamminedichloroplatinum I) is a platinum-based drug, the mainstay of
anticancer treatment for numerous solid tumors. Since its approval by the FDA in 1978, the …

Resistance to platinum compounds is a major determinant of patient survival in high-grade
serous ovarian cancer (HGSOC). To understand mechanisms of platinum resistance and …

To improve the understanding of chemo-refractory high-grade serous ovarian cancers
(HGSOCs), we characterized the proteogenomic landscape of 242 (refractory and sensitive) …

Accurate prediction of cancer drug response (CDR) is a longstanding challenge in modern
oncology that underpins personalized treatment. Current computational methods implement …

Abstract Background Patient-derived organoids (PDOs) from advanced colorectal cancer
(CRC) patients could be a key platform to predict drug response and discover new …

The development of chemoresistance is a major hurdle for the treatment of colorectal cancer
(CRC), which contributes remarkably to the poor clinical prognosis. Nanodrug delivery …

To validate the effect of metal ions in analogous ligand scaffolds on DNA binding and
cytotoxic response, we have synthesized a series of water-soluble ionic N …

Background High-risk neuroblastoma is a complex genetic disease that is lethal in more
than 50% of patients despite intense multimodal therapy. Through genome-wide association …

Purpose To explore fecal immune-related proteins that can be used for colorectal cancer
(CRC) diagnosis. Patients and methods Three independent cohorts were used in present …